China Biotech Services Holdings Limited (stock code: 8037) announced that the resolution regarding the Subscription Agreement, the issuance of the Convertible Bonds, and the granting of a specific mandate to the Board for allotting and issuing the corresponding conversion shares was approved at a special general meeting on 5 February 2026.

According to the poll results disclosed, 499,559,068 shares (100%) voted in favor, with none against. The total number of issued shares as of the meeting date was 975,731,150, all of which were eligible to vote on the resolution. There were no shareholders required to abstain or who chose to abstain from the vote, and no shareholders indicated an intention to vote against the resolution. As more than half of the votes were cast in favor, the resolution was passed as an ordinary resolution.

It was also noted that most directors attended the meeting in person or by electronic means, with a share registrar in Hong Kong appointed as the scrutineer for the poll. The chairman, Liu Xiaolin, served as the executive director leading this announcement, dated 5 February 2026.